<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Background.</bold> The effects of first-line chemoradiotherapy on overall survival (OS) may be confounded by subsequent lines of therapy in patients with limited-stage disease small cell lung cancer (LD-SCLC). Therefore, we aimed to determine the relationships between progression-free survival (PFS), post-progression survival (PPS) and OS after first-line chemoradiotherapy in LD-SCLC patients.<bold>Patients and methods.</bold> We retrospectively analyzed 71 LD-SCLC patients with performance status (PS) 0-2 who received first-line chemoradiotherapy and had disease recurrence between September 2002 and March 2013 at Shizuoka Cancer Center (Shizuoka, Japan). We determined the correlation between PFS and OS and between PPS and OS at the individual level. In addition, we performed univariate and multivariate analyses to identify significant prognostic factors of PPS.<bold>Results.</bold> OS is more strongly correlated with PPS (Spearman’s <italic>r</italic> = 0.86, <italic>R</italic>2 = <italic>0.72, p</italic> &lt; 0.05) than PFS (Spearman’s <italic>r</italic> = 0.46, <italic>R</italic>2 = <italic>0.38, p</italic> &lt; 0.05). In addition, the response to second-line treatments, the presence of distant metastases at recurrence and the number of additional regimens after first-line chemoradiotherapy were significant independent prognostic factors for PPS.<bold>Conclusions.</bold> PPS has more impact on OS than PFS in recurrent LD-SCLC patients with good PS at beginning of the treatment. Moreover, treatments administered after first-line chemoradiotherapy may affect their OS. However, larger multicenter studies are needed to validate these findings.</abstract>

Background. The effects of first-line chemoradiotherapy on overall survival (OS) may be confounded by subsequent lines of therapy in patients with limited-stage disease small cell lung cancer (LD-SCLC). Therefore, we aimed to determine the relationships between progression-free survival (PFS), post-progression survival (PPS) and OS after first-line chemoradiotherapy in LD-SCLC patients.Patients and methods. We retrospectively analyzed 71 LD-SCLC patients with performance status (PS) 0-2 who received first-line chemoradiotherapy and had disease recurrence between September 2002 and March 2013 at Shizuoka Cancer Center (Shizuoka, Japan). We determined the correlation between PFS and OS and between PPS and OS at the individual level. In addition, we performed univariate and multivariate analyses to identify significant prognostic factors of PPS.Results. OS is more strongly correlated with PPS (Spearman’s r = 0.86, R2 = 0.72, p < 0.05) than PFS (Spearman’s r = 0.46, R2 = 0.38, p < 0.05). In addition, the response to second-line treatments, the presence of distant metastases at recurrence and the number of additional regimens after first-line chemoradiotherapy were significant independent prognostic factors for PPS.Conclusions. PPS has more impact on OS than PFS in recurrent LD-SCLC patients with good PS at beginning of the treatment. Moreover, treatments administered after first-line chemoradiotherapy may affect their OS. However, larger multicenter studies are needed to validate these findings.

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

Division of Thoracic Oncology, Shizuoka Cancer Center, Japan

Clinical Trial Coordination Office, Shizuoka Cancer Center, Japan

Division of Radiation Oncology, Shizuoka Cancer Center, Japan

Division of Diagnostic Radiology, Shizuoka Cancer Center, Japan

Division of Diagnostic Pathology, Shizuoka Cancer Center, Japan

Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan

Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Japan

Radiology and Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Background. The effects of first-line chemoradiotherapy on overall survival (OS) may be confounded by subsequent lines of therapy in patients with...

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

Published Online: Nov 27, 2015

Page range: 409 - 415

Received: Jan 31, 2015

Accepted: Jul 06, 2015

DOI: https://doi.org/10.1515/raon-2015-0037

Keywords
chemoradiotherapy, limited-stage disease small cell lung cancer, overall survival, post-progression survival, progression-free survival

© 2015 Norimitsu Kasahara et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

Published Online: Nov 27, 2015

Page range: 409 - 415

Received: Jan 31, 2015

Accepted: Jul 06, 2015

DOI: https://doi.org/10.1515/raon-2015-0037

Keywordschemoradiotherapy, limited-stage disease small cell lung cancer, overall survival, post-progression survival, progression-free survival

© 2015 Norimitsu Kasahara et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Keywords
chemoradiotherapy, limited-stage disease small cell lung cancer, overall survival, post-progression survival, progression-free survival